NCT04453852View on ClinicalTrials.gov

Monovalent Recombinant COVID19 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

April 14, 2021

Conditions
Coronavirus InfectionCOVID
Interventions
BIOLOGICAL

COVID19 vaccine

COVID19 recombinant spike protein with Advax-SM adjuvant

BIOLOGICAL

Saline

Saline control

Trial Locations (1)

5000

PARC,, Adelaide

All Listed Sponsors
collaborator

Central Adelaide Local Health Network Incorporated

OTHER_GOV

lead

Vaxine Pty Ltd

INDUSTRY

NCT04453852 - Monovalent Recombinant COVID19 Vaccine | Biotech Hunter | Biotech Hunter